AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients.

The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points to momentum building over the longer term.

If you are looking beyond AbbVie for oncology and biotech peers using next generation tools, it could be a useful time to scan for other opportunities in healthcare AI via the 39 healthcare AI stocks

With AbbVie stock posting a strong 1 year total return yet trading at a sizeable discount to some intrinsic value estimates and to analyst price targets, is the recent pullback a chance to buy, or is the market already pricing in future growth?

Most Popular Narrative: 12.6% Undervalued

AbbVie is trading at $221.59 against a most followed fair value narrative of $253.55, which frames the stock as modestly undervalued on analyst assumptions.

Continued robust growth in immunology from Skyrizi and Rinvoq, buoyed by expanded prescribing across multiple high-need indications like IBD and dermatology, and further supported by ongoing launches and indication expansions, is likely to drive sustained top-line revenue growth and mitigate the impact of Humira's LOE.

Want to understand why this AbbVie fair value sits comfortably above today’s share price? The narrative leans on compounding revenue, rising margins and a richer earnings mix over time.

Result: Fair Value of $253.55 (UNDERVALUED)

However, AbbVie’s reliance on a concentrated group of immunology and neuroscience drugs, along with exposure to tighter global drug pricing, could challenge the optimistic fair value narrative.

Another View on AbbVie Stock: Earnings Multiple Sends a Different Signal

While the analyst narrative and fair value of $253.55 frame AbbVie as 12.6% undervalued, the current P/E of 108.9x tells a more cautious story versus a fair ratio of 37.4x, the US Biotechs average of 16.4x, and a 20.4x peer average. That kind of gap can mean investors are accepting higher valuation risk for AbbVie, so how comfortable are you with paying such a premium for the earnings profile being modeled?

To see how those earnings multiples stack up against detailed valuation work, review the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern around AbbVie, it makes sense to look at the underlying data yourself and decide quickly where you stand, then weigh those views against the balance of 2 key rewards and 4 important warning signs

Looking for more AbbVie stock ideas and beyond?

If AbbVie has your attention, do not stop here. Use focused stock lists to spot opportunities faster, compare quality, and avoid leaving potential ideas on the table.

• Target resilient income by reviewing companies built around reliable payouts with the 9 dividend fortresses
• Hunt for quality at a reasonable price by scanning the 47 high quality undervalued stocks
• Spot under the radar opportunities with strong fundamentals through the screener containing 20 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.